Yahoo Web Search

Search results

  1. Genmab is a leading biotech company that develops and commercializes antibody medicines for cancer and other serious diseases. Learn about their products, science, partnerships, investors, news and career opportunities.

    • Who We Are

      Delivering on our promise for patients. Founded in 1999 in...

    • Medicines

      We would like to show you a description here but the site...

    • Partnering

      In June 2021, Genmab and Bolt entered into an oncology...

    • Locations

      Genmab US, Inc. 777 Scudders Mill Road Plainsboro, NJ 08536...

  2. en.wikipedia.org › wiki › GenmabGenmab - Wikipedia

    Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen , Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht , The Netherlands , Genmab U.S., Inc. in Princeton ...

  3. Genmab is a biotech company that creates antibody-based treatments for cancer and other serious diseases. Learn about their unique approach, research, collaboration, and patient support.

  4. 6 days ago · Company Announcement. Genmab has completed acquisition of ProfoundBio for USD 1.8 billion in cash. Acquisition gives Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio’s novel antibody-drug conjugate technology platforms.

  5. Genmab is a biotechnology company that develops innovative antibody-based medicines for various indications. Learn about its products, technologies, and clinical trials in different stages of development.

  6. Genmab is a dual-listed, international biotechnology company that develops differentiated antibody medicines to fight against cancer and other serious diseases. Learn about its vision, purpose, values, achievements, pipeline, science and career opportunities.

  7. Apr 3, 2024 · Genmab, a biotechnology company developing antibody therapies for cancer, will acquire ProfoundBio, a clinical-stage biotech with next-generation ADCs. The deal will give Genmab worldwide rights to three candidates in clinical development, including Rina-S, a potential best-in-class FRα-targeted ADC for ovarian cancer.

  8. People also ask

  1. People also search for